Thomas E. Sharp III

Has grant

Assistant Professor

University of South Florida

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Open

Alcohol-induced Gut Dysbiosis and Cardiovascular Disease

Open Date: 2022-03-01

Close Date: 2027-02-01

Grant: Close

“Combined Cell Therapy and Renal Denervation to Prevent Heart Failure after Myocardial Infarction”

Open Date: 2018-01-01

Close Date: 2020-01-01

Grant: Close

“Cortical Bone Stem Cells to Repair the Post MI Heart”

Open Date: 2014-01-01

Close Date: 2016-01-01

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Joseph A. Hill

University of Texas Southwestern Medical Center

UNITED STATES

View details

Jake Doiron

Louisiana State University Health Sciences Center

UNITED STATES

View details

John W. Elrod

Lewis Katz School of Medicine at Temple University

UNITED STATES

View details

Eric Lazartigues

Southeast Louisiana Veterans Health Care System

UNITED STATES

View details

David Kass

Professor, Researcher, Lab Director

Johns Hopkins University

UNITED STATES

View details

Fadi Salloum

Professor of Medicine - Congdon Endowed Chair, VCU Pauley Heart Center

Virginia Commonwealth University Medical Center

UNITED STATES

View details

John Calvert

Associate Professor

Emory University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas E. Sharp III

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (14)

Common Heart Failure With Preserved Ejection Fraction Animal Models Yield Disparate Myofibril Mechanics

Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction

Thromboxane A2 blockade attenuates ethanol‐induced myocardial inflammation: Sipping from the same bottle

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction

Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a “2‐Hit” Murine Model

Hydrogen Sulfide Modulates Endothelial–Mesenchymal Transition in Heart Failure

Mitochondrial H 2 S Regulates BCAA Catabolism in Heart Failure

Nitric Oxide Therapy Attenuates Heart Failure with Preserved Ejection Fraction

Role of S-nitrosoglutathione reductase (GSNOR) Dysregulation and Nitrosative Stress in Heart Failure With Preserved Ejection Fraction

Novel Göttingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities

Reply: Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?

Endothelial Cell Cystathionine γ‐Lyase Expression Level Modulates Exercise Capacity, Vascular Function, and Myocardial Ischemia Reperfusion Injury

Endothelial Cell Cystathionine γ‐Lyase Expression Level Modulates Exercise Capacity, Vascular Function, and Myocardial Ischemia Reperfusion Injury

Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury.

Collaborators (7)

Joseph A. Hill

Jake Doiron

John W. Elrod

Eric Lazartigues

David Kass

Fadi Salloum

John Calvert

Make your next move.